Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
This study has been completed.
Study NCT00138983 Information provided by UMC Utrecht
First Received: August 29, 2005 Last Updated: November 28, 2006
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Rheumatoid Arthritis
Polymyalgia Rheumatica
Giant Cell Arteritis
Polymyositis
Wegener’s Granulomatosis
Additional conditions recognized in this trial
Arteritis
Arthritis
Arthritis, Rheumatoid
Osteoporosis
Rheumatic Diseases
Wegener Granulomatosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Bone Diseases
Bone Diseases, Metabolic
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Kidney Diseases
Lung Diseases
Lung Diseases, Interstitial
Muscular Diseases
Musculoskeletal Diseases
Myositis
Nervous System Diseases
Neuromuscular Diseases
Respiratory Tract Diseases
Skin Diseases
Skin Diseases, Vascular
Urologic Diseases
Vascular Diseases
Vasculitis
Vasculitis, Central Nervous System
Additional drug interventions recognized in this trial
1-hydroxycholecalciferol
Alendronate
Glucocorticoids
Hydroxycholecalciferols
More general drug interventions related to this trial
Bone Density Conservation Agents
Growth Substances
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Vitamins
Sponsors listed in this trial
UMC Utrecht
Dutch Health Care Insurance Board
Back to top of Main Content
